TP53 and hepatocellular carcinoma: For example, the characterization of 363 HCC cases includes WNT signaling (44%), p53 (31%) and Telomerase (TERT promoter mutations in 44%), CDKN2A silencing in 53% as well as broader genomic alterations in the TGF-β signaling (43%).